Advertisement

Dihydroergotamine Mesylate Injection

[01 December 2014]

Products Affected - Description

Dihydroergotamine mesylate injection, BenVenue (formerly Bedford product)
1 mg/mL, 1 mL vial, 10 count (NDC 55390-0013-10)
 
D.H.E. 45, Valeant Pharmaceuticals
1 mg/mL, 1 mL ampule, 10 count (NDC 66490-0041-01)

Reason for the Shortage

  • Ben Venue has stopped production in its plant in Bedford, Ohio and closed in 2014.
  • Valeant cannot provide a reason for the shortage of dihydroergotamine mesylate injection.

Available Products

Dihydroergotamine mesylate injection, Paddock Labs (Perrigo)
1 mg/mL, 1 mL ampule, 5 count (NDC 00574-0850-05)
1 mg/mL, 1 mL ampule, 10 count (NDC 00574-0850-10)

Estimated Resupply Dates

Valeant has D.H.E. 45 injection on back order and the company cannot estimate a release date.

Related Shortages

Updated

December 1, 2014; November 17, 2014; October 20, 2014; October 3, 2014; September 10, 2014; August 29, 2014; July 9, 2014; June 10, 2014; May 21, 2014; May 5, 2014; March 31, 2014; March 17, 2014; February 24, 2014; January 29, 2014; January 3, 2014; December 17, 2013; November 13, 2013; October 10, 2013; September 16, 2013; August 14, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement